Prosecution Insights
Last updated: November 12, 2026
Application No. 18/729,309

2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR

Non-Final OA §102
Filed
Jul 16, 2024
Priority
Jan 17, 2022 — CN PCT/CN2022/072306 +2 more
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suzhou Puhe BioPharma Co., Ltd.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
893 granted / 1150 resolved
+17.7% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
55 currently pending
Career history
1183
Total Applications
across all art units

Office Action

§102
DETAILED ACTION 1. Claims 1-2, 10-13, 17-22, 27-28, 32-33, 35, 37-39 are pending in the instant application. Applicant's election with traverse of group (I), claims 1-2, 10-13, 17-22, 27-28, 32-33 in the reply filed on 08/05/2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Examiner agree to rejoin groups (I-IV), claims 1-2, 10-13, 17-22, 27-28, 32-33. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are examined. Claims 35, 37-39 are withdrawn per 37 CFR 1.142(b). 3. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Dineen et al., WO 2022271630. Dineen et al. discloses the instant claimed compound, which from the STN search is PNG media_image1.png 68 742 media_image1.png Greyscale PNG media_image2.png 998 796 media_image2.png Greyscale PNG media_image3.png 84 788 media_image3.png Greyscale PNG media_image4.png 854 776 media_image4.png Greyscale PNG media_image5.png 306 428 media_image5.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Dineen et al. 4. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Nagasaka et al., Journal of Thoracic Oncology (2021), 16(5), 740-763. Nagasaka et al. discloses the instant claimed compound, which from the STN search is PNG media_image6.png 82 756 media_image6.png Greyscale PNG media_image7.png 358 478 media_image7.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Nagasaka et al. 5. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Meredith et al., Journal of Medicinal Chemistry (2022), 65(14), 9662-9677. Meredith et al. discloses the instant claimed compound, which from the STN search is PNG media_image8.png 92 792 media_image8.png Greyscale PNG media_image9.png 258 436 media_image9.png Greyscale , PNG media_image10.png 332 814 media_image10.png Greyscale , PNG media_image11.png 328 784 media_image11.png Greyscale , PNG media_image12.png 712 772 media_image12.png Greyscale , PNG media_image13.png 328 780 media_image13.png Greyscale , PNG media_image14.png 724 822 media_image14.png Greyscale , PNG media_image15.png 336 788 media_image15.png Greyscale , PNG media_image16.png 726 854 media_image16.png Greyscale , PNG media_image17.png 338 794 media_image17.png Greyscale , PNG media_image18.png 328 790 media_image18.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Meredith et al. 6. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Brooijmans et al., WO 2022271612. Brooijmans et al. discloses the instant claimed compound, which from the STN search is PNG media_image19.png 64 754 media_image19.png Greyscale PNG media_image20.png 618 760 media_image20.png Greyscale . PNG media_image21.png 270 494 media_image21.png Greyscale , PNG media_image22.png 318 780 media_image22.png Greyscale , PNG media_image23.png 316 806 media_image23.png Greyscale , PNG media_image24.png 336 764 media_image24.png Greyscale , PNG media_image25.png 636 806 media_image25.png Greyscale , PNG media_image26.png 696 840 media_image26.png Greyscale , which anticipates the instant compounds. Therefore, the instant claims are anticipated by Brooijmans et al. 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 08/15/2026
Read full office action

Prosecution Timeline

Jul 16, 2024
Application Filed
Aug 20, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790314
SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
2y 7m to grant Granted Nov 10, 2026
Patent 12758529
USE OF EDARAVONE IN TREATMENT OF AUTISM SPECTRUM DISORDER
2y 5m to grant Granted Oct 13, 2026
Patent 12758538
Crystalline Forms of Apalutamide
2y 4m to grant Granted Oct 13, 2026
Patent 12753181
COMPOUNDS FOR DEGRADATION OF CYCLIN-DEPENDENT KINASE 7(CDK7)
2y 10m to grant Granted Oct 06, 2026
Patent 12735419
PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE
3y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-2.9%)
Low
PTA Risk
Based on 1150 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month